Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration
- PMID: 38669557
- PMCID: PMC11191501
- DOI: 10.3233/JPD-230390
Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration
Abstract
Background: Misfolded α-synuclein can be detected in blood samples of Parkinson's disease (PD) patients by a seed amplification assay (SAA), but the association with disease duration is not clear, yet.
Objective: In the present study we aimed to elucidate whether seeding activity of misfolded α-synuclein derived from neuronal exosomes in blood is associated with PD diagnosis and disease duration.
Methods: Cross-sectional samples of PD patients were analyzed and compared to samples of age- and gender-matched healthy controls using a blood-based SAA. Presence of α-synuclein seeding activity and differences in seeding parameters, including fluorescence response (in arbitrary units) at the end of the amplification assay (F60) were analyzed. Additionally, available PD samples collected longitudinally over 5-9 years were included.
Results: In the cross-sectional dataset, 79 of 80 PD patients (mean age 69 years, SD = 8; 56% male) and none of the healthy controls (n = 20, mean age 70 years, SD = 10; 55% male) showed seeding activity (sensitivity 98.8%). When comparing subgroups divided by disease duration, longer disease duration was associated with lower α-synuclein seeding activity (F60: p < 0.001). In the longitudinal analysis 10/11 patients showed a gradual decrease of α-synuclein seeding activity over time.
Conclusions: This study confirms the high sensitivity of the blood-based α-synuclein SAA applied here. The negative association of α-synuclein seeding activity in blood with disease duration makes this parameter potentially interesting as biomarker for future studies on the pathophysiology of disease progression in PD, and for biologically oriented trials in this field.
Keywords: Parkinson’s disease; alpha-synuclein; biomarker.
Conflict of interest statement
ES received grants from the University of Kiel (intramural research funding) and Germany society for Parkinson’s Disease (DPG e.V.), and speaker honoraria from Bayer Vital GmbH, Novartis Pharma GmbH, BIAL GmbH and the Movement Disorder Society outside the submitted work. AK has received research grants from the Michael J. Fox Foundation outside the submitted work. CS, CD, JB, and JW have nothing to report. WM has served on advisory boards of AbbVie, Biogen, Lundbeck, Market Access & Pricing Strategy GmbH, Orion Corporation, Techspert.io and Critical Path for Parkinson's Consortium and has received speaker’s honoraria from AbbVie, Bayer, GlaxoSmithKline, Licher MT, Neuro-Kolleg Online-Live, Rölke Pharma, Takeda, UCB Pharma GmbH, Kyowa Kirin International, and Ology Medical Education outside the submitted work. He was reimbursed consulting fees from EMEA Medical Education Steering Committee for Parkinson’s disease and received grants from Lundbeck, Neuroalliance, European Union, German Federal Ministry of Education of Research, Michael J Fox Foundation, Robert Bosch Foundation, and Sivantos outside the submitted work. DB has received grants or contracts from the German Research Society (DFG), German Parkinson’s Disease Association (dPV), Michael J. Fox Foundation, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, Novartis Pharma GmbH, Damp Foundation, and Lundbeck and has received speaker’s honoraria from AbbVie, Biogen, BIAL, UCB Pharma GmbH, Novartis Pharma GmbH, and Desitin outside the submitted work. She has served on advisory boards of Biogen, BIAL, UCB Pharma GmbH and AC Immune SA outside the submitted work. The TREND-Study is being and was supported by University Hospital Tübingen, German Center for Neurodegenerative Diseases (DZNE), Hertie Institute for Clinical Brain Research (HIH), Christian-Albrechts-University of Kiel, and University Hospital Schleswig-Holstein. Until 2017, subprojects were co-funded by Centre for Integrative Neuroscience (CIN), TEVA Pharmaceutical Industries Ltd, UCb, Janssen Pharmaceuticals, Inc. and International Parkinson Fonds. DB is an Editorial Board Member of this journal but was not involved in the peer-review process nor had access to any information regarding its peer-review.
Figures



Similar articles
-
Detecting Misfolded α-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.Mov Disord. 2024 Aug;39(8):1289-1299. doi: 10.1002/mds.29766. Epub 2024 Apr 23. Mov Disord. 2024. PMID: 38651526
-
A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.Eur J Neurol. 2020 Jun;27(6):967-974. doi: 10.1111/ene.14208. Epub 2020 Apr 13. Eur J Neurol. 2020. PMID: 32150777
-
Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease.Neurotherapeutics. 2020 Jul;17(3):1104-1119. doi: 10.1007/s13311-020-00842-5. Neurotherapeutics. 2020. PMID: 32236821 Free PMC article.
-
The α-Synuclein Seeding Amplification Assay for Parkinson's Disease.Int J Mol Sci. 2025 Jan 4;26(1):389. doi: 10.3390/ijms26010389. Int J Mol Sci. 2025. PMID: 39796243 Free PMC article. Review.
-
Seeding amplification assay: Limitations and insights for enhanced clinical and research applications.J Parkinsons Dis. 2025 May;15(3):447-458. doi: 10.1177/1877718X251325124. Epub 2025 Mar 2. J Parkinsons Dis. 2025. PMID: 40025787 Review.
Cited by
-
Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers.Cells. 2025 Aug 18;14(16):1272. doi: 10.3390/cells14161272. Cells. 2025. PMID: 40862750 Free PMC article. Review.
-
Alpha-Synuclein Seed Amplification Assays in Parkinson's Disease: A Systematic Review and Network Meta-Analysis.Clin Pract. 2025 Jun 3;15(6):107. doi: 10.3390/clinpract15060107. Clin Pract. 2025. PMID: 40558225 Free PMC article. Review.
-
α-Synuclein seeding amplification assays for diagnosing synucleinopathies: an innovative tool in clinical implementation.Transl Neurodegener. 2024 Nov 21;13(1):56. doi: 10.1186/s40035-024-00449-2. Transl Neurodegener. 2024. PMID: 39574205 Free PMC article. Review.
-
A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson's disease.Acta Neuropathol Commun. 2024 Oct 22;12(1):167. doi: 10.1186/s40478-024-01873-1. Acta Neuropathol Commun. 2024. PMID: 39439002 Free PMC article.
-
Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies.Int J Mol Sci. 2024 Sep 19;25(18):10068. doi: 10.3390/ijms251810068. Int J Mol Sci. 2024. PMID: 39337560 Free PMC article. Review.
References
-
- Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou W-Q, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9, 62. - PMC - PubMed
-
- Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, Roeben B, Mammana A, Zimmermann M, Hauser A-K, Deuschle C, Schulte C, Waniek K, Lachmann I, Sjödin S, Brinkmalm A, Blennow K, Zetterberg H, Gasser T, Parchi P (2021) Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9, 175. - PMC - PubMed
-
- Compta Y, Painous C, Soto M, Pulido-Salgado M, Fernández M, Camara A, Sánchez V, Bargalló N, Caballol N, Pont-Sunyer C, Buongiorno M, Martin N, Basora M, Tio M, Giraldo DM, Pérez-Soriano A, Zaro I, Muñoz E, Martí MJ, Valldeoriola F (2022) Combined CSF α-SYNRT-QuIC, CSF NFL and midbrain-pons planimetry in degenerativeparkinsonisms: From bedside to bench, and back again. Parkinsonism Relat Disord 99, 33–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous